MLN0128 is a second-generation TORC1/2 inhibitor that showed preclinical activity in MCC cell lines, decelerating tumor cell growth, diminishing cell proliferation, inducing apoptosis, and enhancing antitumor effect when combined with JQ1 (a bromodomain protein BRD4 inhibitor) (94). The gene discussed is CRTC1; the disease is neoplasm.